References:

1. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation. 2003; 108: 275-281.
2. Ottervanger JP, Armstrong P, Barnathan ES, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina; one-year survival in the GUSTO IV-ACS (Global Use of Strategies to Open Occluded Coronary Arteries IV-Acute Coronary Syndrome) trial. Circulation. 2003; 107: 437-442.
3. Crockett H. BNP: A convenient and cost-effective rule-out tool for heart failure. Clin Lab Int. 2004; 28: 18-19.
4. Allen P. Congestive heart failure and beyond. Clin Lab News. 2003; 29(7): 1,6,8.
5. PBNP Flex® Reagent Cartridge Package Insert. Siemens Healthcare Diagnostics. RF423 PN 755423.001.
6. Yeo K-T J, Wu AHB, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003; 338: 107-115.
7. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. Available at: http://www.nacb.org/lmpg/card_biomarkers_lmpg_draft.stm. Accessed May 7, 2004.
8. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides. A review. Clin Chem. 2004; 50(1): 33-50.